Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HNGE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsHinge Health reports 53% revenue growth, raises guidance, acquires Cylinder Health for $105M
Filed August 4, 2026 · Period ending July 29, 2026 · ~1 min read
Key Changes
-
high
Signed definitive agreement to acquire Cylinder Health for $105M cash to expand into gastrointestinal care, targeting $135B annual market affecting 25% of U.S. adults; expected to close Q3 2026
Item 8.01 — Other Events verify on EDGAR → -
high
Q2 2026 revenue grew 53% YoY to $212.8M; GAAP diluted EPS $0.52 vs. $(13.10) prior year; non-GAAP diluted EPS $0.59 vs. $0.30; free cash flow tripled to $99.6M from $32.6M
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
Raised full-year 2026 revenue guidance to $856M–$860M (46% growth at midpoint) and non-GAAP operating income to $236M–up to $244M (101% growth, 28% margin at midpoint)
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
Board approved $300M increase to share repurchase authorization on July 29, 2026, bringing total authorization to $496.5M; $196.5M already repurchased under prior program
Item 8.01 — Other Events verify on EDGAR → -
medium
Q3 2026 guidance: revenue $223M–up to $225M (45% growth at midpoint), non-GAAP operating income $61M–up to $63M (104% growth, 28% margin at midpoint)
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR →
Summary
Hinge Health reported strong Q2 2026 results with revenue up 53% year-over-year to $212.8 million and a sharp swing to GAAP profitability ($0.52 diluted EPS versus a $13.10 loss in Q2 2025). Free cash flow more than tripled to $99.6 million.
The company raised full-year revenue guidance to $856–$860 million and non-GAAP operating income guidance to $236–up to $244 million, reflecting 101% operating income growth and 28% margin at the midpoint. The company announced a $105 million cash acquisition of Cylinder Health, a virtual-first digestive healthcare provider with nearly 100 clients covering two million lives.
The deal targets the gastrointestinal care market, which affects roughly one in four U.S. adults and represents $135 billion in annual medical spending. Hinge Health plans to integrate Cylinder's clinical expertise with its AI-powered platform to launch a unified GI Care Program in 2027. The transaction is expected to close in Q3 2026. The board also approved a $300 million increase to the share repurchase authorization, bringing total authorization to $496.5 million. The company had already repurchased $196.5 million under the prior program. The combination of strong operating performance, capital deployment for growth through acquisition, and shareholder returns through buybacks signals confidence in the business trajectory.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Hinge Health announced Q2 2026 financial results via press release and scheduled a conference call for August 4, 2026.
Added in current filing · verify on EDGAR →
On August 4, 2026, Hinge Health, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026.
The company disclosed its second quarter 2026 financial results through a press release. The 8-K does not provide specific financial figures; those details are contained in the attached press release exhibit.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
the Company also announced that it would hold a conference call to discuss these financial results on August 4, 2026 at 1:30 p.m. Pacific time (4:30 p.m. Eastern time).
The company scheduled a conference call for the same day as the press release to discuss the quarterly results with investors and analysts.
Added in current filing · verify on EDGAR →
The Company makes reference to non-GAAP financial information in the press release and on the conference call. A reconciliation of these non-GAAP financial measures to their nearest GAAP equivalents is provided in the press release.
The company disclosed that it uses non-GAAP financial measures in its earnings materials and provided reconciliations to GAAP measures in the press release exhibit.
Event · Item 7.01 — Regulation FD Disclosure
Hinge Health posted supplemental investor materials on its IR website under Regulation FD.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On August 4, 2026, the Company posted supplemental investor materials on the investor relations section of its website (ir.hingehealth.com).
The company disclosed that it posted supplemental investor materials on its IR website. The filing does not specify the content of these materials. This is a routine Regulation FD disclosure informing investors where to find company information.
Event · Item 8.01 — Other Events
Hinge Health increased its share repurchase authorization by $300M and announced acquisition of Cylinder Health, Inc.
Added in current filing · verify on EDGAR →
The Company announced on August 4, 2026, that it entered into a definitive agreement to acquire Cylinder Health, Inc. (the “Cylinder Acquisition”). The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026.
Hinge Health entered into a definitive agreement to acquire Cylinder Health, Inc. The transaction is expected to close in Q3 2026, subject to customary closing conditions. No financial terms were disclosed in the 8-K filing.
Event · Exhibit 99.1
Hinge Health reported Q2 2026 revenue of $213M (+53% YoY), raised full-year guidance, and signed a definitive agreement to acquire Cylinder Health for $105M cash.
Added in current filing · view on EDGAR →
Signed a definitive agreement to acquire Cylinder Health, Inc., a leader in virtual-first digestive healthcare, for $105 million in cash consideration. The acquisition will combine Cylinder Health’s clinical expertise and existing market footprint with Hinge Health’s AI-powered care model and technology platform to deliver support in a single app with an integrated Gastrointestinal Care Program, expected to launch in 2027. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026.
Hinge Health is acquiring Cylinder Health for $105 million in cash to expand into gastrointestinal care. The deal is expected to close in Q3 2026 and will integrate Cylinder's clinical expertise with Hinge's AI-powered platform to launch a new GI care program in 2027.
Added in current filing · view on EDGAR →
Full Year 2026: We are raising our revenue guidance to be between $856 million and $860 million, reflecting year-over-year growth of 46% at the midpoint. We are raising our non-GAAP income from operations guidance to be between $236 million and $244 million, reflecting year-over-year growth of 101% and non-GAAP operating margin of 28% at the midpoint.
Hinge Health raised its full-year 2026 revenue guidance to $856–$860 million (46% growth at midpoint) and non-GAAP operating income guidance to $236–$244 million (101% growth at midpoint, 28% margin). The raise reflects strong Q2 performance and confidence in the remainder of the year.
Added in current filing · view on EDGAR →
Q3 2026: We expect revenue to be between $223 million and $225 million, reflecting year-over-year growth of 45% at the midpoint. We expect non-GAAP income from operations to be between $61 million and $63 million, reflecting year-over-year growth of 104% and non-GAAP operating margin of 28% at the midpoint.
For Q3 2026, Hinge Health expects revenue of $223–$225 million (45% growth at midpoint) and non-GAAP operating income of $61–$63 million (104% growth at midpoint, 28% margin). The guidance reflects continued strong growth and margin expansion.
Event · Exhibit 99.2
Added in current filing · view on EDGAR →
Hinge Health, Inc. (NYSE: HNGE) today announced that it has signed a definitive agreement to acquire Cylinder Health, Inc, a leader in virtual-first digestive healthcare, for $105 million in cash consideration.
Hinge Health signed a definitive agreement to acquire Cylinder Health for $105 million in cash. The acquisition aims to expand Hinge Health's offerings into gastrointestinal care, complementing its existing musculoskeletal and migraine care programs. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026.
Added in current filing · view on EDGAR →
GI conditions affect roughly one in four U.S. adults and drive $135 billion in annual medical spend, yet care remains fragmented and difficult to access.
The acquisition targets a large underserved market where GI conditions affect approximately 25% of U.S. adults and represent $135 billion in annual medical spending. The market is characterized by fragmented care and limited access, with 69% of U.S. counties lacking a gastroenterologist, creating significant opportunity for virtual-first care delivery.
Added in current filing · view on EDGAR →
With nearly 100 clients across two million lives, partnerships with two of the three largest PBMs, and three of the top five health plans by self-insured market share, Cylinder has already treated over 150,000 people with a clinically-validated ROI.
Cylinder Health brings established market presence with nearly 100 clients covering two million lives, partnerships with major PBMs and health plans, and a track record of treating over 150,000 people with clinically-validated return on investment. This existing infrastructure provides Hinge Health immediate scale in the GI care market.
Added in current filing · view on EDGAR →
The acquisition will combine Cylinder’s clinical expertise and existing market footprint with Hinge Health’s AI-powered care model and technology platform to deliver support in a single app expected to launch in 2027.
Hinge Health plans to integrate Cylinder's clinical expertise with its AI-powered care model and technology platform to launch a unified GI Care Program within its existing app in 2027. This integration aims to provide members with support across multiple condition areas in a single platform.
Added in current filing · view on EDGAR →
The acquisition is subject to customary closing conditions. It is expected to close in the third quarter of 2026.
The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026. The forward-looking statements acknowledge risks including potential failure of closing conditions, integration challenges, and the possibility that expected benefits may not be realized within the expected timeframe.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 5, 2026 · How we verify